Navigation Links
OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
Date:2/12/2013

ability, tumor response rates and the effect of therapy on Hsp27 levels and circulating tumor cells.

Borealis-2 will be conducted at approximately 30 sites in the U.S. and is being sponsored by the Hoosier Oncology Group. Dr. Noah Hahn from the Indiana University Simon Cancer Center, Dr. Toni Choueiri from the Dana-Farber Cancer Institute and Dr. Jonathan Rosenberg from Memorial Sloan-Kettering Cancer Center will serve as the primary investigators on the study.

ABOUT ORCA
The "ORCA" (Overcoming Resistance in CAncer) program encompasses the on-going studies of OGX-427 aiming to demonstrate that inhibition of Hsp27 can lead to improved prognosis and treatment outcomes for cancer patients. Phase 2 clinical trials are underway in prostate and bladder cancers, with additional studies expected to initiate this year. For more information on OGX-427 and ORCA, please visit www.oncogenex.com.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Teradata (NYSE: TDC ), the ... company, today announced the newest analytic innovation ... Life Sciences helps organizations integrate and analyze data ... (RED), clinical analysis, Real-World Evidence (RWE), and finance. ... can benefit by bringing safer, more effective treatments ...
(Date:4/20/2015)... , April 20, 2015 Pharmaceutical Research and ... $51.2 billion last year in the research and development ... represents the majority of all biopharmaceutical R&D spending – ... United States . The new R&D numbers, the ... are highlighted in the newly released PhRMA ...
(Date:4/20/2015)... Ill. , April 20, 2015  U.S. pharmacy cost ... expected to drift into the low double-digits by 2016, according ... talent, retirement and health solutions business of Aon plc ... design changes are projected to be 9.5 percent in 2015 ... Aon Hewitt predicts a similar rate of increase ...
Breaking Medicine Technology:Teradata Delivers Big Analytics Innovation for Life Sciences 2Teradata Delivers Big Analytics Innovation for Life Sciences 3Teradata Delivers Big Analytics Innovation for Life Sciences 4PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 2PhRMA Member Companies Invested $51.2 Billion in R&D in 2014 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4
... Laboratories, Inc. (OTCBB: UGNE), a leader in ... therapeutics, today announced the Company,s Vice President of ... presenting at IBC,s 4th Annual AsiaTIDES Oligonucleotide and ... Hotel in Tokyo, Japan. The TIDES ...
... DIEGO, Feb. 27, 2012 Optimer Pharmaceuticals, Inc. (NASDAQ: ... and fiscal year 2011 financial results and provide a ... the NASDAQ Global Market closes on March 7th.  The ... at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). ...
Cached Medicine Technology:Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 2Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference 3Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results 2
(Date:4/20/2015)... April 21, 2015 The National ... Binau, Founder of Soul Care Group, Inc., as ... is recognized with this prestigious distinction for leadership in ... Local Chapters, NAPW is the nation's leading networking organizaiton ... Susan with our Woman of the Year Award,” says ...
(Date:4/20/2015)... 20, 2015 Global Lyme Alliance (GLA) ... last Saturday at the Hyatt Regency Greenwich, raised over ... Lyme and other debilitating tick-borne diseases. , “We ... and families who made this year’s Gala such a ... advancing research and education initiatives to ultimately find a ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Saint Joseph Regional ... 15 Top Health Systems by Truven Health Analytics, a leading ... quality of healthcare. SJRMC has been recognized by Truven Health ... the past four years. , According to Truven Health Analytics' ... Health Systems, in matchups with their peers, set the standard ...
(Date:4/20/2015)... Mauritius is a seemingly idyllic and tranquil island oasis ... miles) off the southeastern coast of Africa, the tiny ... where everyone lives together in harmony. , But the ... with drug abuse. In fact, it carries a dubious ... nation in eastern Africa. , “Many youngsters, they know ...
(Date:4/20/2015)... A recent cross-sectional survey involving ... the top 10 most beneficial therapies for fibromyalgia, no drugs ... harmful therapies, only approved drugs were named. , “The ... their effect is only felt as long as the patient ... interview. , “On the other hand, aerobic exercise and other ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Susan Binau, Founder of Soul Care Group, Inc., a 2015 Professional Woman of the Year 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 2Health News:Global Lyme Alliance's “Time for Lyme” Gala Raises Over $850,000 for Tick-Borne Disease Research 3Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Medical Doctor in Huntsville Reveals That Aerobic Exercise Offers Best Results in Fibromyalgia Treatment 2
... by researchers from Trinity College and the Research Institute for ... current smokers, and obtains insight into how to quit smoking ... have successfully managed to do so. Functional ... never smokers performed tasks designed to assess specific cognitive skills ...
... A motor regulatory protein can block human ovarian tumor ... new therapies to treat the disease, according to Penn ... an estimated 21,880 new cases and 13,850 deaths occurred ... most common forms of ovarian cancer and the most ...
... This release is available in German . ... play in future energy supplies? What are the elemental processes ... regeneratively in this manner? How do viruses manage to cross ... viral hosts? What constitutes a healthy thyroid gland metabolism? How ...
... racesespecially Blacksare more willing than Whites to expend personal ... lung or colorectal cancer, even if it means using ... the conclusion of a new study published early online ... American Cancer Society. Delivering quality cancer care that is ...
... Steven Reinberg HealthDay Reporter , MONDAY, April ... Tai chi may improve quality of life for people ... chi combines flowing circular movements, balance and weight-shifting, breathing ... shown to be helpful with a number of medical ...
... your brain healthy, it turns out that visiting friends, attending ... good for you as crossword puzzles. According to research ... help to prevent or delay cognitive decline in old age. ... Journal of the International Neuropsychological Society . The researchers ...
Cached Medicine News:Health News:Brain imaging demonstrates that former smokers have greater willpower 2Health News:Motor protein may offer promise in ovarian cancer treatment 2Health News:DFG establishes 13 new priority programs 2Health News:DFG establishes 13 new priority programs 3Health News:DFG establishes 13 new priority programs 4Health News:Racial differences in willingness to exhaust personal finances for life-sustaining care 2Health News:Tai Chi May Help Heart Failure Patients 2Health News:Tai Chi May Help Heart Failure Patients 3Health News:Higher levels of social activity decrease the risk of cognitive decline 2
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
The popular E2002 Utrata Capsulorhexis Forceps with fine angled sharp tips. Angled 12 mm shafts with an iris stop. Flat handle with dull finish....
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Medicine Products: